{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T23:55:10Z","timestamp":1770508510651,"version":"3.49.0"},"reference-count":31,"publisher":"Informa UK Limited","issue":"10","funder":[{"name":"Chugai Pharmaceutical Co., Ltd, Tokyo, Japan"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2020,10,2]]},"DOI":"10.1080\/13696998.2020.1791890","type":"journal-article","created":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T20:02:41Z","timestamp":1593806561000},"page":"1130-1141","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Cost-effectiveness analysis of treatment regimens with obinutuzumab plus chemotherapy in Japan for untreated follicular lymphoma patients"],"prefix":"10.1080","volume":"23","author":[{"given":"Shinya","family":"Ohno","sequence":"first","affiliation":[{"name":"Global Regulatory Science, Gifu Pharmaceutical University","place":["Gifu, Japan"]},{"name":"Chugai Pharmaceutical Co., Ltd","place":["Tokyo, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Shoji","sequence":"additional","affiliation":[{"name":"Medilead, Inc","place":["Tokyo, Japan"]},{"name":"Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo","place":["Tokyo, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyohiko","family":"Hatake","sequence":"additional","affiliation":[{"name":"International University of Health and Welfare","place":["Tokyo, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Oya","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd","place":["Tokyo, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ataru","family":"Igarashi","sequence":"additional","affiliation":[{"name":"Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo","place":["Tokyo, Japan"]},{"name":"Unit of Public Health and Preventive Medicine, Yokohama City University School of Medicine","place":["Yokohama, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,7,23]]},"reference":[{"issue":"9","key":"e_1_3_3_2_1","first-page":"696","article-title":"Lymphoma study group of Japanese pathologists","volume":"50","author":"The World Health Organization Classification of malignant lymphomas in japan: incidence of recently recognized entities.","year":"2000","unstructured":"The World Health Organization Classification of malignant lymphomas in japan: incidence of recently recognized entities. Lymphoma study group of Japanese pathologists. Pathol Int. 2000;50(9):696\u2013702.","journal-title":"Pathol Int"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12659"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv376"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01073"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.1.140"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2017.1377178"},{"key":"e_1_3_3_8_1","doi-asserted-by":"crossref","unstructured":"Marcus R Davies A Ando K et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331\u20131344.","DOI":"10.1056\/NEJMoa1614598"},{"key":"e_1_3_3_9_1","volume-title":"Ann Hematol","author":"Davies A","year":"2020","unstructured":"Davies A, Trask P, Demeter J, et\u00a0al. Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma. Ann Hematol. 2020."},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0740-4"},{"key":"e_1_3_3_11_1","unstructured":"National Institute for Health and Care Excellence. Obinutuzumab for untreated advanced follicular lymphoma [Internet]. London: NICE; 2018; [cited 2020 Mar]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta513"},{"key":"e_1_3_3_12_1","unstructured":"National Institute for Health and Care Excellence. Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia [Internet]. London: NICE; 2015; [cited 2020 Mar]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta343"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1551532"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7534"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24492"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"e_1_3_3_17_1","first-page":"486","article-title":"Long term follow-up of the PRIMA study: half of patients receiving rituximab maintenance remain progression free at 10 years","volume":"130","author":"Salles GA","year":"2017","unstructured":"Salles GA, Seymour JF, Feugier P, et\u00a0al. Long term follow-up of the PRIMA study: half of patients receiving rituximab maintenance remain progression free at 10 years. Blood. 2017;130:486.","journal-title":"Blood"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.509.509"},{"issue":"1","key":"e_1_3_3_19_1","first-page":"486","article-title":"Long term follow-up of the PRIMA study: half of patients receiving rituximab maintenance remain progression free at 10 years","volume":"130","author":"Salles GA","year":"2017","unstructured":"Salles GA, Seymour JF, Feugier P, et\u00a0al. Long term follow-up of the PRIMA study: half of patients receiving rituximab maintenance remain progression free at 10 years. Am Soc Hematol. 2017;130(Suppl. 1):486.","journal-title":"Am Soc Hematol"},{"key":"e_1_3_3_20_1","unstructured":"Center for Outcomes Research and Economic Evaluation for Health National Institute of Public Health (C2H). Guideline for preparing cost-effectiveness evaluation to the Central Social Insurance Medical Council Version 2.0 [Internet]; 2019; [cited 2019 Sep 5]. Available from: https:\/\/c2h.niph.go.jp\/en\/tools\/guideline\/index.html"},{"key":"e_1_3_3_21_1","unstructured":"Center for Outcomes Research and Economic Evaluation for Health National Institute of Public Health (C2H). Full scale introduction of cost-effectiveness evaluations in Japan: overview (2\/20\/2019) [Internet]; 2019; [cited 2019 Sep 5]. Available from: https:\/\/c2h.niph.go.jp\/tools\/system\/overview_en.pdf"},{"key":"e_1_3_3_22_1","unstructured":"Director-General for Statistics and Information Policy Ministry of Health Labour and Welfare. The 22nd life tables [Internet]; 2015; [cited 2019 Sep 5]. Available from: https:\/\/www.mhlw.go.jp\/english\/database\/db-hw\/lifetb22nd\/dl\/tables.pdf"},{"key":"e_1_3_3_23_1","unstructured":"Population as of 1st of January in 2015 [Internet]; 2015; [cited 2019 Sep 5]. Available from: https:\/\/www.stat.go.jp\/data\/jinsui\/pdf\/201501.pdf"},{"key":"e_1_3_3_24_1","unstructured":"Averages of height and weight per sex and age. Tokyo Japan: Statistics Bureau Ministry of Internal Affairs and Communications; 2018."},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.3820\/jjpe.21.23"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12199-010-0201-y"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-491514"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1098-3015(10)63491-2"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-6-84"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-012-0419-2"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007991003712258"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-8-50"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2020.1791890","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T23:17:59Z","timestamp":1770419879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2020.1791890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,23]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10,2]]}},"alternative-id":["10.1080\/13696998.2020.1791890"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2020.1791890","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-05-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}